About PredOmix
PredOmix is a Healthcare company based in Gurugram (India) founded in 2018 by Kanury Venkata Subba Rao. It operates as a developer of cancer detection blood test. PredOmix has raised $661.7 thousand across 1 funding round from investors including Manish Shashikant Anadkat and Indu Rao. PredOmix was last valued at $3.31 million in June 2019. Its website predomix.com draws about 28 thousand monthly visits. Its Indian entity Predomix Technologies Private Limited reported revenue of βΉ6.61 Cr. PredOmix offers products and services including OncoVeryx Test. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
PredOmix was founded in 2018 and is headquartered in Gurugram, India. The company operates in the health technology sector, focusing on oncology diagnostics. A proprietary technology called OncoVeryx-F is utilized, which combines metabolomics analysis with deep learning algorithms. This approach enables early cancer detection through a single, non-invasive blood test. Operations emphasize research and development for accessible diagnostic solutions in the Indian market and beyond.
- Headquarters Gurugram, India
- Founders Kanury Venkata Subba Rao
- Stage Minicorn
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website predomix.com
- Social LinkedIn X Facebook Instagram
- Legal Name Predomix Technologies Pvt. Ltd.
- Date of Incorporation 31 Aug, 2018
- Jurisdiction Gurgaon, Haryana, India
- Annual Revenue₹6.61 Cr
FY 2024 · -13% YoY
- Net Loss-₹8.2 Lakh
FY 2024 · -1% margin
- EBITDA₹1.50 Cr
FY 2024 · 23% margin
- Total Equity Funding$661.7K (USD)
in 1 rounds
- Latest Funding Round$661.7K (USD), Seed
Jun 2019
Associated legal entities of PredOmix
PredOmix is associated with 2 registered companies on The Company Check; the primary company is Predomix Technologies Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Predomix Technologies Private Limited CIN U73200HR2018PTC075459 | Active | 31 Aug 2018 | Gurgaon, Haryana | ₹6.6 Cr | 17 | 2 | View details |
| Predomixai Private Limited CIN U73100HR2019PTC082600 | Strike Off | 17 Sep 2019 | Gurugram, Haryana | – | – | 2 | View details |
Products & Services of PredOmix
PredOmix offers a comprehensive portfolio of products and services, including OncoVeryx Test.
Blood test for early detection of multiple cancers using metabolomics.
Funding Insights of PredOmix
PredOmix has successfully raised a total of $661.7K through 1 strategic funding round. The most recent funding activity was a Seed round of $661.7 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $661,696
- Total Rounds 1
- Last Round Seed β $661,696
- First Round $661,696
(Jun 2019)
- Investors Count 2
All 1 funding rounds of PredOmix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $661,696 | Seed | $3.31M | Manish Shashikant Anadkat |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2019 | $3.31M | β’β’β’β’β’β’β’β’ |
Last known valuation $3.31M (Jun 2019). 2 investors in total: 0 institutional and 2 angel.
Investors in PredOmix
PredOmix has secured backing from 2 investors, including angel investors. Prominent investors backing the company include Manish Shashikant Anadkat and Indu Rao.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
MS Manish Shashikant Anadkat | - | – | unknown_bf0f058e8f2641ec8 | - |
IR Indu Rao | - | – | unknown_ce30fe94e285489a8 | - |
Investor details for PredOmix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Predomix Technologies Private Limited (PredOmix)
Predomix Technologies Private Limited is the primary company behind PredOmix. The boards of the 2 registered companies of PredOmix currently have 3 directors; the longest-serving is Kanury Venkata Subba Rao, appointed in 2018. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kanury Venkata Subba Rao DIN 06844158 | Director | 31 Aug 2018 | 8 yrs 1 mo | Predomix Technologies Private Limited, Predomixai Private Limited |
| Manish Shashikant Anadkat DIN 08575020 | Director | 20 Sep 2019 | 7 yrs 1 mo | Predomix Technologies Private Limited |
| Indu Rao DIN 02371365 | Director | 15 May 2020 | 6 yrs 5 mo | Predomixai Private Limited |
People of PredOmix
1 people are tracked at PredOmix (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Co-Founder | Leadership |
Complete people profiles for PredOmix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of PredOmix
Figures of Predomix Technologies Private Limited, the primary company behind PredOmix, for FY 2024. Revenue was ₹6.61 Cr (-13% year on year). Net loss was -₹8.2 Lakh (-1% margin). EBITDA was ₹1.50 Cr (23% margin). Revenue has grown at a compounded annual rate of +31% over three years.
- ₹6.61 CrRevenue · FY 2024 · -13% YoY
- -₹8.2 LakhNet loss · -1% margin
- ₹1.50 CrEBITDA · 23% margin
- ₹1.4 LakhPaid-up capital
- 17Employees (provident fund records)
- +31%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Predomix Technologies Private Limited are on its company page.
Detailed financial statements for PredOmix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of PredOmix
3 dated milestones of PredOmix across 1 years, from founding to its latest funding, stage changes and deals.
- Founded PredOmix is founded.
- Funding First funding round of $662K.
- Milestone Reaches Minicorn status.
Competitors of PredOmix
PredOmix has 9 listed competitors in our database, 8 of them funded. They include Guardant Health, Natera, Foundation Medicine, ArcherDX and Prenetics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| prenetics.com | 2009 | Hong Kong, China | $67.65M | – | Health risks are identified through online genetic and diagnostic testing. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. | |
| veracyte.com | 2008 | San Francisco, United States | $67.9M | 815 | Genomics-based diagnostic tests for cancer are developed. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | – | Provider of DNA sequencing for cancer detection | |
| exactsciences.com | 1995 | Madison, United States | – | 6,600 | Non-invasive molecular diagnostic tests for cancer detection are provided. |
Detailed competitors of PredOmix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PredOmix
The website of PredOmix (predomix.com) receives about 27.8K visits a month.
- Monthly visits27.8K
▲ 6.8% vs previous month
Top companies in Oncology
10 companies that operate in the same segment as PredOmix (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Predomix
Complete news archive for PredOmix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PredOmix
PredOmix was founded in 2018 and raised its 1st funding round 1 year after it was founded.
PredOmix is headquartered in Gurugram, India. It is registered at Gurugram, Haryana, India.
PredOmix is a funded company, having raised a total of $661.7K across 1 funding round to date. The company's 1st funding round was a Seed of $661.7K, raised on Jun 2019.
The primary company behind PredOmix, Predomix Technologies Private Limited, reported revenue of βΉ6.61 Cr for FY 2024, down 13% year on year.
PredOmix was founded in 2018 and is headquartered in Gurugram, India. The company operates in the health technology sector, focusing on oncology diagnostics. A proprietary technology called OncoVeryx-F is utilized, which combines metabolomics analysis with deep learning algorithms. This approach enables early cancer detection through a single, non-invasive blood test. Operations emphasize research and development for accessible diagnostic solutions in the Indian market and beyond.
PredOmix's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
PredOmix offers OncoVeryx Test.
PredOmix has 2 investors. Key investors include Manish Shashikant Anadkat, and Indu Rao.
The valuation of PredOmix is $3.31M as of Jun 2019.
PredOmix is associated with 2 legal entities: Predomix Technologies Private Limited, Predomixai Private Limited.
The legal entities of PredOmix currently have 3 directors, including Manish Shashikant Anadkat, Kanury Venkata Subba Rao, Indu Rao.